SPRO Spero Therapeutics Inc

Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference to be held in New York, NY, September 9th – 11th, 2024. He will also participate in a fireside chat and be available for one-on-one meetings at Cantor’s Global Healthcare Conference in New York, NY, September 17th – 19th, 2024. Details are as follows:

H.C. Wainwright 26th Annual Global Investment Conference
Presentation Date:	September 10, 2024
Time:	4:00 - 4:30 PM ET
Webcast link:	Company Presentation
Cantor’s Global Healthcare Conference
Analyst Fireside Chat:	September 17, 2024
Time:	1:20 - 1:50 PM ET
Webcast link:	Fireside Chat

The webcasts may also be accessed through Spero’s website on the “Events and Presentations” page (https://www.sperotherapeutics.com/investor-relations). A replay will be available on the website following the conclusion of the event.

About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections. For more information, visit https://sperotherapeutics.com.

Investor Relations Contact:Shai Biran, PhDSpero TherapeuticsIR@Sperotherapeutics.com

Media Inquiries: media@sperotherapeutics.com